IL-22 Signaling in the Tumor Microenvironment

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Interleukin-22 (IL-22) is part of the IL-10 cytokine family, mediating functions via heterodimer receptors (IL-22R1/IL-10R2).
• IL-22 is primarily produced by immune cells like T cells and natural killer cells.
• The IL-22 receptor (IL-22R1) is expressed on non-immune cells, including epithelial and liver cells.

Purpose of the Study:

• To review the multifaceted roles of IL-22 in malignant cells and immunocytes within the tumor microenvironment (TME).
• To discuss the potential of IL-22 as a therapeutic target for drug discovery in cancer.

Main Methods:

• Literature review of studies investigating IL-22 production, receptor binding, and downstream signaling pathways.
• Analysis of research on IL-22's indirect regulation of the TME.
• Exploration of IL-22's involvement in malignant cells and immunocytes.

Main Results:

• IL-22 activates key signaling pathways including STAT, NF-κB, MAPK, and PI3K/AKT/mTOR.
• Despite immune cells not directly responding to IL-22, it indirectly modulates the TME.
• IL-22 influences various non-immune cells, impacting tumor progression and immune responses.

Conclusions:

• IL-22 plays a complex, indirect role in the tumor microenvironment, affecting both cancer cells and immune cells.
• Understanding IL-22's functions offers potential for novel cancer drug discovery and therapeutic strategies.